^
Association details:
| Biomarker: | PIM1 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Brukinsa (zanubrutinib) (BTK inhibitor) |
| Drug Class: | CD20 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BIOMARKER IDENTIFICATION IN RELAPSED/REFRACTORY NON-GERMINAL CENTER B-CELL–LIKE DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ZANUBRUTINIB
Published date:
06/27/2020
Excerpt:
For the 56 non-GCB patients with HTG gene expression profiles, PAX5 expression was significantly higher in monotherapy responders, and PIM1, BCL2, and FOXP1 expression was higher in combination therapy responders....Zanubrutinib alone or in combination with an anti-CD20 antibody showed activity in the overall non-GCB DLBCL population.
